 Neurotoxicity Syndromes
"Neurotoxicity Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method. This includes conditions caused by biologic, chemical, and pharmaceutical agents.
| Descriptor ID |
D020258
|
| MeSH Number(s) |
C10.720 C25.723.705
|
| Concept/Terms |
Neurotoxicity Syndromes- Neurotoxicity Syndromes
- Neurotoxicity Syndrome
- Syndrome, Neurotoxicity
- Syndromes, Neurotoxicity
- Neurotoxin Disorders
- Neurotoxin Disorder
- Neurotoxic Disorders
- Neurotoxic Disorder
- Neurotoxin Diseases
- Neurotoxin Disease
- Poisoning, Nervous System
- Nervous System Poisonings
- Poisonings, Nervous System
- Nervous System Poisoning
Encephalopathy, Toxic- Encephalopathy, Toxic
- Encephalopathies, Toxic
- Toxic Encephalopathies
- Toxic Encephalopathy
Toxic Encephalitis- Toxic Encephalitis
- Encephalitides, Toxic
- Encephalitis, Toxic
- Toxic Encephalitides
|
Below are MeSH descriptors whose meaning is more general than "Neurotoxicity Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Neurotoxicity Syndromes".
This graph shows the total number of publications written about "Neurotoxicity Syndromes" by people in this website by year, and whether "Neurotoxicity Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2002 | 1 | 0 | 1 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2008 | 1 | 0 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 3 | 1 | 4 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Neurotoxicity Syndromes" by people in Profiles.
-
Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist. 2019 08; 24(8):1039-e642.
-
Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017 11 21; 5(1):95.
-
Ginat DT. MRI of toxic leukoencephalopathy syndrome associated with methylenedioxymethamphetamine. Neurology. 2015 Feb 17; 84(7):757.
-
Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst. 2014 Mar 12; 106(5).
-
Robson MJ, Seminerio MJ, McCurdy CR, Coop A, Matsumoto RR. s Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacol Rep. 2013; 65(2):343-9.
-
Seminerio MJ, Hansen R, Kaushal N, Zhang HT, McCurdy CR, Matsumoto RR. The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. Int J Neuropsychopharmacol. 2013 Jun; 16(5):1033-44.
-
Kaushal N, Seminerio MJ, Robson MJ, McCurdy CR, Matsumoto RR. Pharmacological evaluation of SN79, a sigma (s) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Eur Neuropsychopharmacol. 2013 Aug; 23(8):960-71.
-
Zacny JP, Paice JA, Coalson DW. Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav. 2012 Jan; 100(3):560-5.
-
Zhu H, Bhattacharyya BJ, Lin H, Gomez CM. Skeletal muscle IP3R1 receptors amplify physiological and pathological synaptic calcium signals. J Neurosci. 2011 Oct 26; 31(43):15269-83.
-
Torres-Altoro MI, Mathur BN, Drerup JM, Thomas R, Lovinger DM, O'Callaghan JP, Bibb JA. Organophosphates dysregulate dopamine signaling, glutamatergic neurotransmission, and induce neuronal injury markers in striatum. J Neurochem. 2011 Oct; 119(2):303-13.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|